Virotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and clinical settings. One important challenge to reach the full therapeutic potential of oncolytic adenoviruses is accomplishing efficient infection of cancer cells and avoiding uptake by normal tissue through tropism modification. Towards this goal, we constructed and characterized an oncolytic adenovirus, carrying mutated capsid proteins to abolish the promiscuous adenovirus native tropism and encoding a bispecific adapter molecule to target the virus to the epidermal growth factor receptor (EGFR). The new virus displayed a highly selective targeting profile, with reduced infection of EGFR-negative cells and efficient killing of EGFR-positive cancer ...
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic viroth...
Purpose: Oncolytic viruses are self-amplifying anticancer agents that make use of the natural abilit...
AbstractWe have engineered a human adenovirus, ONYX-411, that selectively replicates in human tumor ...
Virotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and clinica...
AbstractVirotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and...
A promising new strategy for cancer therapy is the use of engineered oncolytic viruses, adapted from...
Conditionally replicating adenoviruses (CRADs) represent a promising new platform for the treatment ...
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic viroth...
Conditionally replicative adenoviruses (CRAds) are potentially useful agents for anticancer virother...
Cancer gene therapy with conditionally replicating adenoviruses is a powerful way of overcoming low ...
Adenovirus serotype 5 (Ad5) is widely used as an oncolytic agent for cancer therapy. However, its in...
AbstractAn approach combining redundant controls to restrict the productive infection of adenoviruse...
In the 1990s, adenovirus became one of the first virus types to be genetically engineered to selecti...
Immunotherapy has moved to the forefront of modern oncologic treatment in the past few decades. Vari...
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic viroth...
Purpose: Oncolytic viruses are self-amplifying anticancer agents that make use of the natural abilit...
AbstractWe have engineered a human adenovirus, ONYX-411, that selectively replicates in human tumor ...
Virotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and clinica...
AbstractVirotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and...
A promising new strategy for cancer therapy is the use of engineered oncolytic viruses, adapted from...
Conditionally replicating adenoviruses (CRADs) represent a promising new platform for the treatment ...
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic viroth...
Conditionally replicative adenoviruses (CRAds) are potentially useful agents for anticancer virother...
Cancer gene therapy with conditionally replicating adenoviruses is a powerful way of overcoming low ...
Adenovirus serotype 5 (Ad5) is widely used as an oncolytic agent for cancer therapy. However, its in...
AbstractAn approach combining redundant controls to restrict the productive infection of adenoviruse...
In the 1990s, adenovirus became one of the first virus types to be genetically engineered to selecti...
Immunotherapy has moved to the forefront of modern oncologic treatment in the past few decades. Vari...
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic viroth...
Purpose: Oncolytic viruses are self-amplifying anticancer agents that make use of the natural abilit...
AbstractWe have engineered a human adenovirus, ONYX-411, that selectively replicates in human tumor ...